Clearmind Medicine Inc. (Nasdaq: CMND) announced the publication of a U.S. patent application by the United States Patent and Trademark Office covering a combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for use in treating post-traumatic stress disorder, anxiety, and eating disorders.

The application was developed through an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX). The two companies have jointly generated 13 patent applications globally through their collaboration, which integrates NeuroThera's PEA technology into Clearmind's therapeutic programs.

The application claims that PEA may enhance MDMA's therapeutic potency, reduce required dosing, mitigate side effects, and broaden MDMA's therapeutic window. No clinical data supporting these claims was cited in the announcement.

The publication follows the FDA's finalization on July 13, 2026, of guidance titled "Psychedelic Drugs: Considerations for Clinical Investigations." The guidance explicitly includes MDMA within its definition of psychedelic drugs, categorizing it as an "entactogen or empathogen." It addresses trial design, conduct, data collection, subject safety, and new drug application requirements for sponsors developing psychedelic drugs.

Clearmind's overall intellectual property portfolio currently includes 19 patent families and 32 granted patents, according to the company's statement.